CN114146071A - Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome - Google Patents
Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome Download PDFInfo
- Publication number
- CN114146071A CN114146071A CN202210117249.5A CN202210117249A CN114146071A CN 114146071 A CN114146071 A CN 114146071A CN 202210117249 A CN202210117249 A CN 202210117249A CN 114146071 A CN114146071 A CN 114146071A
- Authority
- CN
- China
- Prior art keywords
- methoxyacetophenone
- hydroxy
- paeonol
- bromo
- hydroxyacetophenone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 title claims abstract description 197
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 title claims abstract description 88
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 title claims abstract description 88
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 22
- 208000002741 leukoplakia Diseases 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 32
- 241001465754 Metazoa Species 0.000 claims abstract description 23
- 241000696962 White spot syndrome virus Species 0.000 claims description 57
- -1 2-hydroxy-4-methoxyphenyl Chemical group 0.000 claims description 11
- SULYEHHGGXARJS-UHFFFAOYSA-N 2',4'-dihydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1O SULYEHHGGXARJS-UHFFFAOYSA-N 0.000 claims description 10
- 241000238424 Crustacea Species 0.000 claims description 9
- LYKDOWJROLHYOT-UHFFFAOYSA-N 1-(2-hydroxy-4-methylphenyl)ethanone Chemical compound CC(=O)C1=CC=C(C)C=C1O LYKDOWJROLHYOT-UHFFFAOYSA-N 0.000 claims description 6
- GPVDHNVGGIAOQT-UHFFFAOYSA-N 2,4-dimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C(OC)=C1 GPVDHNVGGIAOQT-UHFFFAOYSA-N 0.000 claims description 6
- KYFBKHRLIHDKPB-UHFFFAOYSA-N 2,5-Dimethoxyphenol Chemical compound COC1=CC=C(OC)C(O)=C1 KYFBKHRLIHDKPB-UHFFFAOYSA-N 0.000 claims description 6
- WZUODJNEIXSNEU-UHFFFAOYSA-N 2-Hydroxy-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C(O)=C1 WZUODJNEIXSNEU-UHFFFAOYSA-N 0.000 claims description 6
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 6
- NTPLXRHDUXRPNE-UHFFFAOYSA-N 4-methoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C=C1 NTPLXRHDUXRPNE-UHFFFAOYSA-N 0.000 claims description 6
- MRIXVKKOHPQOFK-UHFFFAOYSA-N 4-methoxysalicylic acid Chemical compound COC1=CC=C(C(O)=O)C(O)=C1 MRIXVKKOHPQOFK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 6
- QUAMTGJKVDWJEQ-UHFFFAOYSA-N octabenzone Chemical compound OC1=CC(OCCCCCCCC)=CC=C1C(=O)C1=CC=CC=C1 QUAMTGJKVDWJEQ-UHFFFAOYSA-N 0.000 claims description 6
- DXGLGDHPHMLXJC-UHFFFAOYSA-N oxybenzone Chemical compound OC1=CC(OC)=CC=C1C(=O)C1=CC=CC=C1 DXGLGDHPHMLXJC-UHFFFAOYSA-N 0.000 claims description 6
- AGQNLHOTLJFJCG-UHFFFAOYSA-N 1-(2-hydroxy-4-phenylmethoxyphenyl)ethanone Chemical compound C1=C(O)C(C(=O)C)=CC=C1OCC1=CC=CC=C1 AGQNLHOTLJFJCG-UHFFFAOYSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 claims description 5
- KXVQEKFWNOZTQX-UHFFFAOYSA-N 5-bromo-2-hydroxy-4-methoxybenzoic acid Chemical compound COC1=CC(O)=C(C(O)=O)C=C1Br KXVQEKFWNOZTQX-UHFFFAOYSA-N 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- KJCLYACXIWMFCC-UHFFFAOYSA-M sodium;5-benzoyl-4-hydroxy-2-methoxybenzenesulfonate Chemical compound [Na+].C1=C(S([O-])(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 KJCLYACXIWMFCC-UHFFFAOYSA-M 0.000 claims description 4
- SCTZFHGSNSIMHU-UHFFFAOYSA-N 1-(2,4-dihydroxy-3-prop-2-enylphenyl)ethanone Chemical compound CC(=O)C1=CC=C(O)C(CC=C)=C1O SCTZFHGSNSIMHU-UHFFFAOYSA-N 0.000 claims description 3
- HSDSKVWQTONQBJ-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)ethanone Chemical compound CC(=O)C1=CC=C(C)C=C1C HSDSKVWQTONQBJ-UHFFFAOYSA-N 0.000 claims description 3
- PIRRWUMTIBFCCW-UHFFFAOYSA-N 1-(2-fluoro-4-methoxyphenyl)ethanone Chemical compound COC1=CC=C(C(C)=O)C(F)=C1 PIRRWUMTIBFCCW-UHFFFAOYSA-N 0.000 claims description 3
- BCEPNLMYVYJIHU-UHFFFAOYSA-N 1-(2-hydroxy-3,4-dimethoxyphenyl)ethanone Chemical compound COC1=CC=C(C(C)=O)C(O)=C1OC BCEPNLMYVYJIHU-UHFFFAOYSA-N 0.000 claims description 3
- KEQHBVWVKYHDCS-UHFFFAOYSA-N 1-(2-hydroxy-4,5-dimethoxyphenyl)ethanone Chemical compound COC1=CC(O)=C(C(C)=O)C=C1OC KEQHBVWVKYHDCS-UHFFFAOYSA-N 0.000 claims description 3
- LQCMMXGKEGWUIM-UHFFFAOYSA-N 1-(4-bromo-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC=C(Br)C=C1O LQCMMXGKEGWUIM-UHFFFAOYSA-N 0.000 claims description 3
- QCVSDCHNBNFJDQ-UHFFFAOYSA-N 1-(4-chloro-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1O QCVSDCHNBNFJDQ-UHFFFAOYSA-N 0.000 claims description 3
- HLTBTUXAMVOKIH-UHFFFAOYSA-N 1-(4-fluoro-2-hydroxyphenyl)ethanone Chemical compound CC(=O)C1=CC=C(F)C=C1O HLTBTUXAMVOKIH-UHFFFAOYSA-N 0.000 claims description 3
- VQTDPCRSXHFMOL-UHFFFAOYSA-N 2,4-Dimethoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C(OC)=C1 VQTDPCRSXHFMOL-UHFFFAOYSA-N 0.000 claims description 3
- DJPUGKVFRDJSMK-UHFFFAOYSA-N 2-(2-acetyl-5-methoxyphenoxy)acetic acid Chemical compound COC1=CC=C(C(C)=O)C(OCC(O)=O)=C1 DJPUGKVFRDJSMK-UHFFFAOYSA-N 0.000 claims description 3
- HPURPVUTEGLILL-UHFFFAOYSA-N 2-ethyl-5-methoxyphenol Chemical compound CCC1=CC=C(OC)C=C1O HPURPVUTEGLILL-UHFFFAOYSA-N 0.000 claims description 3
- FDRYADKKCJHYJU-UHFFFAOYSA-N 2-hydroxy-4-methoxybenzonitrile Chemical compound COC1=CC=C(C#N)C(O)=C1 FDRYADKKCJHYJU-UHFFFAOYSA-N 0.000 claims description 3
- MAKZPFSTXDXNJN-UHFFFAOYSA-N 2-hydroxy-4-methoxyphenyl ethyl ketone Natural products CCC(=O)C1=CC=C(OC)C=C1O MAKZPFSTXDXNJN-UHFFFAOYSA-N 0.000 claims description 3
- IAMNVCJECQWBLZ-UHFFFAOYSA-N 4-hydroxy-2-methylacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1C IAMNVCJECQWBLZ-UHFFFAOYSA-N 0.000 claims description 3
- JXZABYGWFNGNLB-UHFFFAOYSA-N 4-methoxybenzene-1,2-diol Chemical compound COC1=CC=C(O)C(O)=C1 JXZABYGWFNGNLB-UHFFFAOYSA-N 0.000 claims description 3
- QXIOWYFFTWXSHE-UHFFFAOYSA-N 5-methoxy-2-methylphenol Chemical compound COC1=CC=C(C)C(O)=C1 QXIOWYFFTWXSHE-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- FBUBVLUPUDBFME-UHFFFAOYSA-N Xanthoxylin Chemical compound COC1=CC(O)=C(C(C)=O)C(OC)=C1 FBUBVLUPUDBFME-UHFFFAOYSA-N 0.000 claims description 3
- TVMUHOAONWHJBV-UHFFFAOYSA-M dehydroglycinate Chemical compound [O-]C(=O)C=N TVMUHOAONWHJBV-UHFFFAOYSA-M 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 3
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 claims description 3
- XXRXIXLOPWSNJS-UHFFFAOYSA-N CCC(CC(C=CC(OC)=C1)=C1O)=O Chemical compound CCC(CC(C=CC(OC)=C1)=C1O)=O XXRXIXLOPWSNJS-UHFFFAOYSA-N 0.000 claims description 2
- VBLALYJSGGGWHU-UHFFFAOYSA-N 1-(4-ethoxy-2-hydroxyphenyl)ethanone Chemical compound CCOC1=CC=C(C(C)=O)C(O)=C1 VBLALYJSGGGWHU-UHFFFAOYSA-N 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 8
- 238000011160 research Methods 0.000 abstract description 7
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000002155 anti-virotic effect Effects 0.000 abstract description 2
- 239000003124 biologic agent Substances 0.000 abstract description 2
- 241000318927 Shrimp white spot syndrome virus Species 0.000 abstract 1
- 241000238553 Litopenaeus vannamei Species 0.000 description 51
- 230000004083 survival effect Effects 0.000 description 25
- 241000700605 Viruses Species 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 20
- 238000012360 testing method Methods 0.000 description 18
- 238000001179 sorption measurement Methods 0.000 description 13
- 230000004071 biological effect Effects 0.000 description 11
- 230000000840 anti-viral effect Effects 0.000 description 10
- 238000009360 aquaculture Methods 0.000 description 9
- 244000144974 aquaculture Species 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 241000238557 Decapoda Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003443 antiviral agent Substances 0.000 description 3
- 239000012752 auxiliary agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 102000012440 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229940022698 acetylcholinesterase Drugs 0.000 description 2
- 238000012271 agricultural production Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- RGHQKFQZGLKBCF-UHFFFAOYSA-N 2-bromoethyl acetate Chemical compound CC(=O)OCCBr RGHQKFQZGLKBCF-UHFFFAOYSA-N 0.000 description 1
- ZWVHTXAYIKBMEE-UHFFFAOYSA-N 2-hydroxyacetophenone Chemical compound OCC(=O)C1=CC=CC=C1 ZWVHTXAYIKBMEE-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 102000003669 Antiporters Human genes 0.000 description 1
- 108090000084 Antiporters Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 244000000004 fungal plant pathogen Species 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- DYGBNAYFDZEYBA-UHFFFAOYSA-N n-(cyclopropylmethyl)-2-[4-(4-methoxybenzoyl)piperidin-1-yl]-n-[(4-oxo-1,5,7,8-tetrahydropyrano[4,3-d]pyrimidin-2-yl)methyl]acetamide Chemical compound C1=CC(OC)=CC=C1C(=O)C1CCN(CC(=O)N(CC2CC2)CC=2NC(=O)C=3COCCC=3N=2)CC1 DYGBNAYFDZEYBA-UHFFFAOYSA-N 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Abstract
The invention belongs to the technical field of plant source antivirus, and discloses application of paeonol and derivatives thereof in preventing and treating white spot syndrome of aquatic animals. Animal experiment research shows that paeonol and its derivatives have good effect of resisting white spot syndrome virus WSSV. The paeonol and the derivatives thereof can be used for preparing related treatment drugs for white spot syndrome, and are expected to be developed into green biological agents in aquatic product culture.
Description
Technical Field
The invention belongs to the technical field of plant-derived antiviral drugs, relates to screening of an anti-white spot syndrome virus active substance in aquaculture, and particularly relates to application of paeonol and derivatives thereof in prevention and treatment of white spot syndrome.
Background
Paeonol (2-hydroxy-4-methoxyacetophenone) is a phenolic ketone compound separated from root bark of Paeonia suffruticosa Andr. Paeonol can be extracted from cortex moutan. Because the structure is simple and easy to synthesize, the synthesis raw materials are cheap and easy to obtain, and the synthesis of paeonol is mainly completed by two steps: step one, resorcinol is taken as a raw material, and acetylation is carried out by adopting different methods to prepare 2, 4-dihydroxy acetophenone; secondly, the prepared 2, 4-dihydroxy acetophenone is further methylated to synthesize 2-hydroxy-4-methoxy acetophenone, namely paeonol.
The paeonol compound has various unique biological effects, and is widely applied to scientific research, clinical medicine and agricultural production. The biological effect is mainly embodied in two aspects: firstly, paeonol can act on acetylcholinesterase (AChE) to obviously influence the normal transmission of nerve impulses at a synaptic site; secondly, the mechanism of transporting paeonol across the blood-brain barrier shows that the paeonol can actively pass through the blood-brain barrier and enter the brain through an H +/OC antiporter. In the aspect of agricultural production, paeonol is mainly used for preventing and treating plant diseases and insect pests, inhibiting plant pathogenic fungi and keeping fruits and vegetables fresh; in clinical medicine, paeonol is mainly used for relieving fever and pain, resisting rheumatism and treating eczema, but the research on the paeonol and the derivatives thereof does not relate to the antiviral activity of animals at present.
White Spot Syndrome Virus (WSSV) caused prawn White spot syndrome virus is the biggest epidemic disease which endangers prawn industries so far. The key points of the disease prevention and control research are mainly focused on immunopotentiators, inactivated virus particle vaccines, RNAi, Chinese herbal medicine extracts, stress-resistant seedling culture and the like. Due to the defects of shrimps in vaccine control, drug control is still the most direct and effective means in production. However, aquatic antiviral drugs such as amantadine, guanine analogues, ribavirin and the like have been banned, and the clinical application of the aquatic antiviral drugs is very limited. Therefore, the development of the innovative research of the antiviral fishing medicine has important significance for meeting the urgent needs of the industry and ensuring the safety and environmental friendliness of aquatic products.
Disclosure of Invention
Paeonol is a micromolecular phenolic compound with a special structure, has wide biological activity, stable chemical property, easily modified structure, low price and easy obtaining, and has a plurality of excellent conditions as a lead structure for drug development. The paeonol and the derivatives thereof have wide prospect in developing new medicaments. The invention aims to explore the feasibility of paeonol and derivatives thereof in the aspect of aquaculture antivirus, and develops a new way for innovative research of antiviral green fishery drugs.
The invention provides application of paeonol in preparing a medicament for resisting crustacean aquatic animal viruses. Based on the experimental animal verification of the invention, paeonol has inhibitory activity on white spot syndrome virus WSSV, and can be used for preventing and treating white spot syndrome of aquatic animals.
In addition, the invention provides the application of the paeonol derivative in preparing the medicament for resisting the virus of the crustacean aquatic animals. Based on the same technical effect, the paeonol derivative can be used for preventing and treating the white spot syndrome of the aquatic animals.
The paeonol derivative is selected from any one or more of the following compounds 1-61.
2, 5-dimethoxyphenol (compound 1), 2-hydroxy-4-methoxybenzonitrile (compound 2), 4-methoxy-1, 2-benzenediol (compound 3), 2-hydroxy-4-methoxybenzoic acid (compound 4), 5-methoxy-2-methylphenol (compound 5), 2-hydroxy-4-methoxybenzaldehyde (compound 6), 2-hydroxy-4-methoxypropiophenone (compound 7), 2-hydroxy-4-methoxyphenylbutanone (compound 8), 2-hydroxy-4-methoxybenzophenone (compound 9), 1- (2-hydroxy-4-methoxyphenyl) -2-acetophenone (compound 10), 2-ethyl-5-methoxyphenol (compound 11), 1- (2-hydroxy-4-methoxybenzene) ethanol (compound 12), paeonol bromide (compound 13), paeonol thiosemicarbazone (compound 14), and potassium paeonol iminoacetate (compound 15);
2, 4-dimethoxyacetophenone (compound 16), 2-allyloxy-4-methoxyacetophenone (compound 17), 2-fluoro-4-methoxyacetophenone (compound 18), 2-acetyl 5-methoxyphenoxyacetic acid (compound 19), p-methoxyacetophenone (compound 20), paeonol acetic acid-2-bromo-ethyl ester (compound 21), paeonol acetic acid-2- (nitrooxy) ethyl ester (compound 22), 2-ethoxy-4-methoxyacetophenone (compound 23), 2-butoxy-4-methoxyacetophenone (compound 24), 2-hexyloxy-4-methoxyacetophenone (compound 25), 2-octyloxy-4-methoxyacetophenone (compound 26), 2-decyloxy-4-methoxyacetophenone (compound 27), 2-dodecyloxy-4-methoxyacetophenone (compound 28), 2-tetradecyloxy-4-methoxyacetophenone (compound 29), 2-hexadecyloxy-4-methoxyacetophenone (compound 30);
2, 4-dihydroxyacetophenone (compound 31), 4-bromo-2-hydroxyacetophenone (compound 32), 4-fluoro-2-hydroxyacetophenone (compound 33), 4-benzyloxy-2-hydroxyacetophenone (compound 34), 4-ethoxy-2-hydroxyacetophenone (compound 35), 2-hydroxy-4-methylacetophenone (compound 36), 4-chloro-2-hydroxyacetophenone (compound 37), 2-hydroxyacetophenone (compound 38), 4-allyloxy-2-hydroxyacetophenone (compound 39);
2-hydroxy-3, 4-dimethoxyacetophenone (compound 40), 2-hydroxy-4, 5-dimethoxyacetophenone (compound 41), 2-hydroxy-4, 6-dimethoxyacetophenone (compound 42), sodium paeonol sulfonate (compound 43), 5-bromo-2-hydroxy-4-methoxyacetophenone (compound 44);
2, 4-dimethoxybenzoic acid (compound 45), 2-4-dihydroxybenzoic acid (compound 46), 2-hydroxy-4-n-octoxybenzophenone (compound 47), 4-hydroxy-2-methylacetophenone (compound 48), 2, 4-dimethylacetophenone (compound 49), p-hydroxyacetophenone (compound 50), 5-bromo-2-hydroxy-4-methoxybenzoic acid (compound 51), 2-hydroxy-4-methoxybenzophenone-5-sodium sulfonate (compound 52), 5-bromo-2-ethoxy-4-methoxyacetophenone (compound 53), 5-bromo-2-butoxy-4-methoxyacetophenone (compound 54), 5-bromo-2-hexyloxy-4-methoxyacetophenone (compound 55), 5-bromo-2-octyloxy-4-methoxyacetophenone (compound 56), 5-bromo-2-decyloxy-4-methoxyacetophenone (compound 57), 5-bromo-2-dodecyloxy-4-methoxyacetophenone (compound 58), 5-bromo-2-tetradecyloxy-4-methoxyacetophenone (compound 59), 5-bromo-2-hexadecyloxy-4-methoxyacetophenone (compound 60), 3-allyl-2, 4-dihydroxyacetophenone (compound 61).
Based on the results of animal experiments, the invention provides a medicament for resisting crustacean aquatic animal white spot syndrome virus, and the active ingredient of the medicament comprises paeonol. The technical personnel in the field can easily know that on the basis that paeonol can be used for preventing and treating white spot syndrome of aquatic animals, the paeonol is combined with a pharmaceutically optional carrier or auxiliary agent to prepare the medicament into a preparation or vaccine convenient for aquaculture. The invention is not limited to the pharmaceutically acceptable carriers or adjuvants.
Based on the results of animal experiments, the invention provides a medicament for resisting crustacean aquatic animal white spot syndrome virus, and the active ingredients of the medicament comprise paeonol derivatives. The paeonol derivative is selected from any one or more of compounds 1-61. The technical personnel in the field can easily know that on the basis that the paeonol derivative can be used for preventing and treating the white spot syndrome of aquatic animals, the paeonol derivative is combined with a pharmaceutically optional carrier or auxiliary agent to prepare the medicament into a preparation or vaccine convenient for aquaculture. The invention is not limited to the pharmaceutically acceptable carriers or adjuvants.
Based on the results of animal experiments, the invention provides a medicament for resisting crustacean aquatic animal white spot syndrome virus, and the active ingredients of the medicament comprise paeonol and paeonol derivatives. The paeonol derivative is selected from any one or more of compounds 1-61. The technical personnel in the field can easily know that the paeonol and the paeonol derivative can be used for preventing and treating the white spot syndrome of aquatic animals, and the medicaments are prepared into a preparation or a vaccine convenient for aquaculture by being matched with a pharmaceutically optional carrier or auxiliary agent. The invention is not limited to the pharmaceutically acceptable carriers or adjuvants.
It is also particularly desirable in view of the wide variety of paeonol derivatives. The invention only verifies the biological activity of the paeonol derivative (compounds 1-61) on the white spot syndrome virus. In light of the teaching or technology of the present invention, those skilled in the art can also continuously verify the white spot syndrome virus inhibiting activity of other paeonol derivatives than the compounds 1-61, the combination of at least two of the paeonol derivatives of the compounds 1-61, the combination of paeonol and at least one of the paeonol derivatives of the compounds 1-61, and the like.
Compared with the prior art, the invention has the following beneficial effects or advantages:
the invention firstly verifies and reveals the biological activity of paeonol and derivatives thereof for resisting white spot syndrome virus. Animal experiment researches show that paeonol and derivatives thereof can obviously inhibit the replication of white spot syndrome virus in bodies of the penaeus vannamei boone and improve the survival rate of the penaeus vannamei boone infected by the white spot syndrome virus. Paeonol and its derivatives have good antiviral effect on white spot syndrome virus in shellfish aquaculture, and can be used for preventing and treating aquatic animal diseases caused by white spot syndrome virus.
The paeonol and the derivatives thereof have the characteristics of low toxicity, low residue, low cost, greenness and safety, and the biological activity of the paeonol and the derivatives thereof can be utilized to prevent and treat white spot syndrome virus which harms crustacean aquaculture, thereby providing a new path for developing and researching green biological agents for aquaculture and expanding new application of the paeonol and the derivatives thereof.
Drawings
FIG. 1 is an absolute quantitative standard curve.
Detailed Description
The present invention will be further described with reference to the following examples and accompanying drawings, but the present invention is not limited to these examples. The embodiment of the invention aims to illustrate the white spot syndrome virus resisting activity of paeonol and derivatives thereof.
Example 1
This example illustrates the determination of the anti-white spot syndrome virus activity of paeonol and its first-position derivative.
(1) Test materials
Virus material: the white spot syndrome virus is provided by the third ocean institute of the national ocean agency and is stored in an aquatic disease laboratory of the northwest agriculture and forestry science and technology university.
Preparing a liquid medicine to be detected: accurately weighing 1-15 standard substances of the compounds respectively, preparing standard solution with concentration of 100 mg/mL by using chromatographic grade methanol, and diluting the standard solution with methanol into different concentrations of 10, 15, 20, 30, 40, 60 and 80 mg/mL; the resulting mixture was filtered through a 0.22 μm organic syringe filter and transferred to a brown chromatographic bottle for use as a standard dilution.
Experimental animals: the test is carried out by adopting penaeus vannamei boone purchased from Shaanxi Yanyang aquatic animals market.
(2) Evaluation of safety
Before the determination of the antiviral activity, the safety evaluation of the paeonol and the derivatives thereof on the penaeus vannamei boone is carried out. Healthy penaeus vannamei boone is randomly selected and grouped into 5 penaeus vannamei boone groups, and the penaeus vannamei boone groups are placed in a plastic box with the water temperature of 25 ℃ for test treatment. The test was set up with a blank control group and a drug treated group. The blank control group was injected with only TM buffer, and the drug-treated group was injected with different concentrations of compound. The tested concentrations of the compounds were: 50. 150 and 200 mg/kg. The injection volume of the drug was 100. mu.L/vial. After the drug injection, the survival status of the shrimps was observed and recorded for 72 hours continuously.
The safety evaluation result shows that the paeonol and the derivatives thereof are safe for the penaeus vannamei boone within the tested time (72 h) and concentration (50-200 mg/kg), and meanwhile, the penaeus vannamei boone does not show uncomfortable symptoms.
(3) Antiviral Activity assay
Healthy penaeus vannamei boone was randomly selected, each was divided into 3 groups (WSSV treatment group, compound and WSSV co-treatment group, blank control group), and 30 each group was subjected to 3 parallel experiments. The test was carried out in a 25 ℃ aquaculture water. The tested concentrations of the compounds were all 50 mg/kg. The volume of the treatment solution for each penaeus vannamei injection is 100. mu.L. The drug treatment method is that the WSSV virus and the monomer compound are premixed and then immediately injected into the abdomen (the virus dosage of each shrimp is 6.9 multiplied by 10)7copies, pre-mix: mixing the virus solution and the medicinal solution at 25 deg.C, and injecting immediately), respectively, after 24 hr, randomly selecting 5 Penaeus vannamei Boone from each treatment group, collecting the branchial tissue of the prawn, and storing at-80 deg.C for use.
The samples collected were used for absolute quantification of the WSSV genomic DNA copy number, respectively. The viral genome copy number in gill tissues of the treated samples was detected using absolute fluorescent quantitative PCR. And extracting the DNA of the collected tissue sample by using a marine animal tissue genome DNA extraction kit. The extracted DNA concentration and purity were measured using a ultramicrospectrophotometer, and then the DNA concentration was adjusted to 50 ng/. mu.L in a lump. The number of viral copies in tissues was quantified by RT-qPCR and an absolute quantitative standard curve constructed (figure 1).
Extracting the DNA of the gill tissue of the penaeus vannamei:
1) weighing about 10 mg of tissue material, fully grinding, putting into a centrifuge tube filled with 200 mu L of GA buffer solution, and carrying out vortex oscillation for 15 sec;
2) adding 20 μ L of protease K (20 mg/mL), mixing by vortex, centrifuging briefly to remove water droplets on the inner wall of the tube cover, standing at 56 deg.C until the tissue is completely dissolved, and centrifuging briefly to remove water droplets on the inner wall of the tube cover;
3) adding 200 μ L buffer solution GB, fully reversing and mixing, standing at 70 deg.C for 10 min, cleaning the solution, and centrifuging briefly to remove water droplets on the inner wall of the tube cover;
4) adding 200 μ L of anhydrous ethanol, mixing thoroughly, wherein flocculent precipitate may appear, and centrifuging briefly to remove water drops on the inner wall of the tube cover;
5) adding the solution and flocculent precipitate obtained in the previous step into adsorption column CB3 (placing the adsorption column into a collecting pipe), centrifuging at 12000 rpm for 30 sec, pouring off waste liquid, and placing adsorption column CB3 back into the collecting pipe;
6) adding 500 μ L buffer GD into adsorption column CB3, centrifuging at 12000 rpm for 30 sec, pouring off waste liquid, and placing adsorption column CB3 into a collection tube;
7) adding 600 μ L of rinsing liquid PW into adsorption column CB3, centrifuging at 12000 rpm for 30 sec, pouring off waste liquid, and placing adsorption column CB3 into a collecting tube;
8) repeating the operation step 7);
9) putting the adsorption column CB3 back into the collecting pipe, centrifuging at 12000 rpm for 2 min, pouring off waste liquid, and placing the adsorption column CB3 at room temperature for a plurality of minutes to thoroughly dry the residual rinsing liquid in the adsorption material;
10) transferring the adsorption column CB3 into a clean centrifuge tube, suspending and dripping 50 mu L of elution buffer solution ddH into the middle part of the adsorption film2O, standing at room temperature for 2-5 min, centrifuging at 12000 rpm for 2 min, and collecting the solution into a centrifuge tube;
11) adding the solution obtained by centrifugation into an adsorption column CB3, standing at room temperature for 2 min, centrifuging at 12000 rpm for 2 min to obtain a DNA product, and storing the DNA product at-20 ℃ for later use.
The PCR quantitative detection was performed in real time using CFX-96. The quantitative primer used was VP28141The primer sequences are shown in Table 1. The quantitative kit uses AceQ qPCR SYBR Green Master Mix of Vazyme. The quantitative reaction system and the reaction procedure are shown in Table 2 and Table 3, respectively.
TABLE 1 primer VP28141Of (2) a
TABLE 2 RT-qPCR reaction System
TABLE 3 RT-qPCR reaction procedure
(4) Survival detection
After the safe concentration is determined, the protective effect of paeonol and the derivatives thereof on the penaeus vannamei boone is tested in vivo. Healthy penaeus vannamei boone was randomly divided into 3 groups of 100 each, and TM buffer (control group), TM-WSSV mixture (positive control group), and drug-WSSV mixture (treatment group, 50 mg/kg) were injected, respectively. Each group of penaeus vannamei was observed for 7 days and the mortality was recorded. Wherein, the survival rate calculation formula is as follows: survival (%) = number of survivors treated group/total number per group x 100%.
TABLE 4 determination of the anti-white spot syndrome Virus Activity of the Paeonol I-position derivative
As can be seen from Table 4, paeonol and the first-position derivative thereof significantly reduce the copy number of WSSV in Penaeus vannamei Boone, and have good biological activity against WSSV, wherein the inhibition rates of 2-hydroxy-4-methoxybenzophenone and 1- (2-hydroxy-4-methoxyphenyl) -2-acetophenone on viruses are the highest and reach 88%.
As can be seen from table 4, paeonol and its derivatives can significantly reduce the mortality rate of WSSV litopenaeus vannamei. During the test, no or only a small amount of the TM buffer treated penaeus vannamei boone died. WSSV treated Penaeus vannamei Boone suffered from massive death, and the survival rate at 8 d was 0%. The survival rate of the sick Penaeus vannamei Boone treated by the paeonol and the first-position derivative thereof is improved, wherein the survival rate of the 2-hydroxy-4-methoxybenzophenone group is the highest and reaches 57%.
As can be seen from table 4, paeonol and its first-order derivatives can significantly inhibit the in vivo replication of WSSV penaeus vannamei, and at the same time, increase the survival rate of WSSV infected penaeus vannamei.
Example 2
This example shows the determination of the anti-white spot syndrome virus activity of paeonol and its derivatives at position two.
The test materials, antiviral activity assay, and absolute quantification of WSSV genomic DNA copy number used in this example were the same as in example 1. The test results are shown in Table 5.
TABLE 5 determination of the anti-white Spot syndrome Virus Activity of the Paeonol No. two derivatives
As can be seen from Table 5, the paeonol and the second-position derivative thereof remarkably reduce the copy number of the WSSV in the bodies of the penaeus vannamei boone, and have good biological activity of resisting the WSSV, wherein the inhibition rate of the 2-allyloxy-4-methoxyacetophenone on viruses is the highest and reaches 89.36 percent.
As can be seen from Table 5, paeonol and its derivatives at the second position can significantly reduce the mortality rate of WSSV-infected Penaeus vannamei Boone. During the test, no or only a small amount of the TM buffer treated penaeus vannamei boone died. WSSV treated Penaeus vannamei Boone suffered from massive death, and the survival rate at 8 d was 0%. The survival rate of the sick Penaeus vannamei Boone treated by paeonol and its derivatives is improved, wherein the survival rate of 2-octyloxy-4-methoxyacetophenone and 2-decyloxy-4-methoxyacetophenone groups is up to 56%.
As can be seen from table 5, paeonol and its derivatives can significantly inhibit the in vivo replication of WSSV penaeus vannamei, and at the same time, increase the survival rate of WSSV infected penaeus vannamei.
Example 3
This example shows the determination of the anti-white spot syndrome virus activity of paeonol and its four-position derivatives.
The test materials, antiviral activity assay, and absolute quantification of WSSV genomic DNA copy number used in this example were the same as in example 1. The test results are shown in Table 6.
TABLE 6 determination of the anti-white spot syndrome Virus Activity of the Paeonol four-position derivative
As can be seen from Table 6, the paeonol and the four-position derivative thereof remarkably reduce the copy number of the WSSV in the bodies of the penaeus vannamei boone, have good biological activity of resisting the WSSV, and the inhibition rate of the 4-benzyloxy-2-hydroxyacetophenone on viruses is the highest and reaches 92 percent.
As can be seen from table 6, paeonol and its four-position derivatives can significantly reduce the mortality rate of WSSV penaeus vannamei. During the test, no or only a small amount of the TM buffer treated penaeus vannamei boone died. WSSV treated Penaeus vannamei Boone suffered from massive death, and the survival rate at 8 d was 0%. The survival rate of the sick Penaeus vannamei Boone treated by paeonol and the derivatives thereof is improved, wherein the survival rate of the 4-benzyloxy-2-hydroxyacetophenone group is the highest and reaches 58%.
As can be seen from table 6, paeonol and its derivatives can significantly inhibit the in vivo replication of WSSV penaeus vannamei, and at the same time, increase the survival rate of WSSV infected penaeus vannamei.
Example 4
This example shows the determination of the anti-white spot syndrome virus activity of paeonol and other site derivatives.
The test materials, antiviral activity assay, and absolute quantification of WSSV genomic DNA copy number used in this example were the same as in example 1. The test results are shown in Table 7.
TABLE 7 determination of the anti-white spot syndrome Virus Activity of the Paeonol four-position derivative
As can be seen from Table 7, the copy number of WSSV in Penaeus vannamei Boone is significantly reduced by paeonol and other derivatives, and the results prove that the paeonol and other derivatives have good biological activity against WSSV, wherein the inhibition rate of 5-bromo-2-hydroxy-4-methoxyacetophenone on viruses is the highest and reaches 85%.
To further demonstrate the anti-WSSV activity of paeonol and other derivatives, as shown in table 7, paeonol and other derivatives were able to significantly reduce the mortality rate of WSSV infected penaeus vannamei. During the test, no or only a small amount of the TM buffer treated penaeus vannamei boone died. WSSV treated Penaeus vannamei Boone suffered from massive death, and the survival rate at 8 d was 0%. The survival rate of the sick Penaeus vannamei Boone treated by paeonol and its derivatives is improved, wherein the survival rate of the sodium paeonol sulfonate group is the highest, and reaches 53%.
In addition, the paeonol and the derivatives thereof can obviously inhibit the in vivo replication of WSSV penaeus vannamei boone and simultaneously improve the survival rate of the WSSV infected penaeus vannamei boone.
Example 5
This example shows the determination of the anti-white spot syndrome virus activity of paeonol and its multi-position derivatives.
The test materials, antiviral activity assay, and absolute quantification of WSSV genomic DNA copy number used in this example were the same as in example 1. The test results are shown in Table 8.
TABLE 8 determination of the anti-white spot syndrome Virus Activity of the Paeonol four-position derivative
As can be seen from Table 8, the paeonol and the multi-position derivatives thereof significantly reduce the copy number of WSSV in Penaeus vannamei Boone, and the results prove that the paeonol and the multi-position derivatives thereof have good biological activity against WSSV, wherein the inhibition rate of 5-bromo-2-hydroxy-4-methoxybenzoic acid on viruses is the highest and reaches 85%.
To further demonstrate the anti-WSSV activity of paeonol and its multi-position derivatives, as shown in table 8, paeonol and its multi-position derivatives were able to significantly reduce the mortality rate of WSSV infected penaeus vannamei. During the test, no or only a small amount of the TM buffer treated penaeus vannamei boone died. WSSV treated Penaeus vannamei Boone suffered from massive death, and the survival rate at 8 d was 0%. The survival rate of the sick Penaeus vannamei Boone treated by paeonol and the derivatives thereof is improved, wherein the survival rate of the 2-hydroxy-4-methoxybenzophenone-5-sodium sulfonate group is the highest and reaches 54 percent.
In addition, the paeonol and the derivatives thereof can obviously inhibit the in vivo replication of WSSV penaeus vannamei boone and simultaneously improve the survival rate of the WSSV infected penaeus vannamei boone.
As described above, the present invention can be preferably implemented, and the above-mentioned embodiments only describe the preferred embodiments of the present invention, and do not limit the scope of the present invention, and various changes and modifications of the technical solution of the present invention made by those skilled in the art without departing from the design spirit of the present invention shall fall within the protection scope defined by the present invention.
Claims (6)
1. Application of paeonol and its derivatives in preparing medicine for preventing and treating white spot syndrome of aquatic animals is provided.
2. Use according to claim 1, characterized in that the paeonol derivative is selected from the group consisting of 2, 5-dimethoxyphenol, 2-hydroxy-4-methoxybenzonitrile, 4-methoxy-1, 2-benzenediol, 2-hydroxy-4-methoxybenzoic acid, 5-methoxy-2-methylphenol, 2-hydroxy-4-methoxybenzaldehyde, 2-hydroxy-4-methoxypropiophenone, 2-hydroxy-4-methoxyphenylbutanone, 2-hydroxy-4-methoxybenzophenone, 1- (2-hydroxy-4-methoxyphenyl) -2-acetophenone, 2-ethyl-5-methoxyphenol, 2-hydroxy-4-methoxybenzophenone, and mixtures thereof, 1- (2-hydroxy-4-methoxybenzene) ethanol, brominated paeonol, paeonol thiosemicarbazone, and potassium paeonol imino acetate;
2, 4-dimethoxyacetophenone, 2-fluoro-4-methoxyacetophenone, 2-acetyl 5-methoxyphenoxyacetic acid, p-methoxyacetophenone, paeonolacetic acid-2-bromo-ethyl ester, paeonolacetic acid-2- (nitrooxy) ethyl ester, 2-ethoxy-4-methoxyacetophenone, 2-butoxy-4-methoxyacetophenone, 2-hexyloxy-4-methoxyacetophenone, 2-octyloxy-4-methoxyacetophenone, 2-decyloxy-4-methoxyacetophenone, 2-dodecyloxy-4-methoxyacetophenone, 2-tetradecyloxy-4-methoxyacetophenone, 2-hexadecyloxy-4-methoxyacetophenone;
2, 4-dihydroxyacetophenone, 4-bromo-2-hydroxyacetophenone, 4-fluoro-2-hydroxyacetophenone, 4-benzyloxy-2-hydroxyacetophenone, 4-ethoxy-2-hydroxyacetophenone, 2-hydroxy-4-methylacetophenone, 4-chloro-2-hydroxyacetophenone, 2-hydroxy-4-ethoxyacetophenone, 4-allyloxy-2-hydroxyacetophenone;
2-hydroxy-3, 4-dimethoxyacetophenone, 2-hydroxy-4, 5-dimethoxyacetophenone, 2-hydroxy-4, 6-dimethoxyacetophenone, sodium paeonol sulfonate, and 5-bromo-2-hydroxy-4-methoxyacetophenone;
2, 4-dimethoxybenzoic acid, 2-4-dihydroxybenzoic acid, 2-hydroxy-4-n-octoxybenzophenone, 4-hydroxy-2-methylacetophenone, 2, 4-dimethylacetophenone, p-hydroxyacetophenone, 5-bromo-2-hydroxy-4-methoxybenzoic acid, 2-hydroxy-4-methoxybenzophenone-5-sodium sulfonate, 5-bromo-2-ethoxy-4-methoxyacetophenone, 5-bromo-2-butoxy-4-methoxyacetophenone, 5-bromo-2-hexyloxy-4-methoxyacetophenone, 5-bromo-2-octyloxy-4-methoxyacetophenone, methyl ethyl phenyl methyl phenyl ethyl, 5-bromo-2-decyloxy-4-methoxyacetophenone, 5-bromo-2-dodecyloxy-4-methoxyacetophenone, 5-bromo-2-tetradecyloxy-4-methoxyacetophenone, 5-bromo-2-hexadecyloxy-4-methoxyacetophenone and 3-allyl-2, 4-dihydroxyacetophenone.
3. The medicine for resisting crustacean aquatic animal white spot syndrome virus is characterized in that the active ingredient of the medicine comprises paeonol.
4. The medicine for resisting crustacean aquatic animal white spot syndrome virus is characterized in that the active ingredient of the medicine comprises paeonol derivatives.
5. The medicine for resisting crustacean aquatic animal white spot syndrome virus is characterized in that active ingredients of the medicine comprise paeonol and paeonol derivatives.
6. The medicament according to claim 4 or 5, wherein the paeonol derivative is selected from the group consisting of 2, 5-dimethoxyphenol, 2-hydroxy-4-methoxybenzonitrile, 4-methoxy-1, 2-benzenediol, 2-hydroxy-4-methoxybenzoic acid, 5-methoxy-2-methylphenol, 2-hydroxy-4-methoxybenzaldehyde, 2-hydroxy-4-methoxypropiophenone, 2-hydroxy-4-methoxybenzophenone, 1- (2-hydroxy-4-methoxyphenyl) -2-acetophenone, 2-ethyl-5-methoxyphenol, 1- (2-hydroxy-4-methoxybenzene) ethanol, brominated paeonol, paeonol thiosemicarbazone, and potassium paeonol imino acetate;
2, 4-dimethoxyacetophenone, 2-fluoro-4-methoxyacetophenone, 2-acetyl 5-methoxyphenoxyacetic acid, p-methoxyacetophenone, paeonolacetic acid-2-bromo-ethyl ester, paeonolacetic acid-2- (nitrooxy) ethyl ester, 2-ethoxy-4-methoxyacetophenone, 2-butoxy-4-methoxyacetophenone, 2-hexyloxy-4-methoxyacetophenone, 2-octyloxy-4-methoxyacetophenone, 2-decyloxy-4-methoxyacetophenone, 2-dodecyloxy-4-methoxyacetophenone, 2-tetradecyloxy-4-methoxyacetophenone, 2-hexadecyloxy-4-methoxyacetophenone;
2, 4-dihydroxyacetophenone, 4-bromo-2-hydroxyacetophenone, 4-fluoro-2-hydroxyacetophenone, 4-benzyloxy-2-hydroxyacetophenone, 4-ethoxy-2-hydroxyacetophenone, 2-hydroxy-4-methylacetophenone, 4-chloro-2-hydroxyacetophenone, 2-hydroxy-4-ethoxyacetophenone, 4-allyloxy-2-hydroxyacetophenone;
2-hydroxy-3, 4-dimethoxyacetophenone, 2-hydroxy-4, 5-dimethoxyacetophenone, 2-hydroxy-4, 6-dimethoxyacetophenone, sodium paeonol sulfonate, and 5-bromo-2-hydroxy-4-methoxyacetophenone;
2, 4-dimethoxybenzoic acid, 2-4-dihydroxybenzoic acid, 2-hydroxy-4-n-octoxybenzophenone, 4-hydroxy-2-methylacetophenone, 2, 4-dimethylacetophenone, p-hydroxyacetophenone, 5-bromo-2-hydroxy-4-methoxybenzoic acid, 2-hydroxy-4-methoxybenzophenone-5-sodium sulfonate, 5-bromo-2-ethoxy-4-methoxyacetophenone, 5-bromo-2-butoxy-4-methoxyacetophenone, 5-bromo-2-hexyloxy-4-methoxyacetophenone, 5-bromo-2-octyloxy-4-methoxyacetophenone, methyl ethyl phenyl methyl phenyl ethyl, 5-bromo-2-decyloxy-4-methoxyacetophenone, 5-bromo-2-dodecyloxy-4-methoxyacetophenone, 5-bromo-2-tetradecyloxy-4-methoxyacetophenone, 5-bromo-2-hexadecyloxy-4-methoxyacetophenone and 3-allyl-2, 4-dihydroxyacetophenone.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210117249.5A CN114146071B (en) | 2022-02-08 | 2022-02-08 | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome |
| CN202210912127.5A CN115040497A (en) | 2022-02-08 | 2022-02-08 | Application of paeonol derivative in preventing and treating leukoplakia syndrome |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210117249.5A CN114146071B (en) | 2022-02-08 | 2022-02-08 | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210912127.5A Division CN115040497A (en) | 2022-02-08 | 2022-02-08 | Application of paeonol derivative in preventing and treating leukoplakia syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114146071A true CN114146071A (en) | 2022-03-08 |
| CN114146071B CN114146071B (en) | 2023-02-28 |
Family
ID=80450184
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210912127.5A Withdrawn CN115040497A (en) | 2022-02-08 | 2022-02-08 | Application of paeonol derivative in preventing and treating leukoplakia syndrome |
| CN202210117249.5A Active CN114146071B (en) | 2022-02-08 | 2022-02-08 | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210912127.5A Withdrawn CN115040497A (en) | 2022-02-08 | 2022-02-08 | Application of paeonol derivative in preventing and treating leukoplakia syndrome |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN115040497A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117180246A (en) * | 2023-11-02 | 2023-12-08 | 西北农林科技大学深圳研究院 | Application of isoliquiritigenin in preparation of medicines for preventing and treating shrimp white spot syndrome |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1416866A (en) * | 2002-11-18 | 2003-05-14 | 文仁肇 | Medicine for preventing and treating diseases of prawn |
| KR20030069506A (en) * | 2002-02-21 | 2003-08-27 | 주식회사 리앤조바이오텍 | Anti-white spot syndrome virus igy |
| CN1596914A (en) * | 2003-09-15 | 2005-03-23 | 徐万富 | Medicine for treating eye disease caused by visceral disease |
| KR20070115017A (en) * | 2006-05-30 | 2007-12-05 | 주식회사 씨티씨바이오 | Composition and method for treating or preventing white spot syndrome virus |
| WO2009153337A1 (en) * | 2008-06-20 | 2009-12-23 | Wageningen Universiteit | Infection inhibitor |
| CN102166205A (en) * | 2010-02-26 | 2011-08-31 | 张筱梅 | New medical application of paeonol and derivatives thereof |
| CN103432292A (en) * | 2013-08-08 | 2013-12-11 | 泰州市春达动物药业饲料有限公司 | Medicine composition for treating white spot syndrome virus disease and preparation method thereof |
| CN105410346A (en) * | 2015-10-30 | 2016-03-23 | 广西中医药大学 | Cultured penaeus vannamei survival rate improving traditional Chinese medicine preparation and preparation method thereof |
| KR102049976B1 (en) * | 2018-07-30 | 2019-11-28 | (주)애드바이오텍 | Antibody for shrimp’s early mortality syndrome and white spot syndrome virus, and applications thereof |
-
2022
- 2022-02-08 CN CN202210912127.5A patent/CN115040497A/en not_active Withdrawn
- 2022-02-08 CN CN202210117249.5A patent/CN114146071B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030069506A (en) * | 2002-02-21 | 2003-08-27 | 주식회사 리앤조바이오텍 | Anti-white spot syndrome virus igy |
| CN1416866A (en) * | 2002-11-18 | 2003-05-14 | 文仁肇 | Medicine for preventing and treating diseases of prawn |
| CN1596914A (en) * | 2003-09-15 | 2005-03-23 | 徐万富 | Medicine for treating eye disease caused by visceral disease |
| KR20070115017A (en) * | 2006-05-30 | 2007-12-05 | 주식회사 씨티씨바이오 | Composition and method for treating or preventing white spot syndrome virus |
| WO2009153337A1 (en) * | 2008-06-20 | 2009-12-23 | Wageningen Universiteit | Infection inhibitor |
| CN102166205A (en) * | 2010-02-26 | 2011-08-31 | 张筱梅 | New medical application of paeonol and derivatives thereof |
| CN103432292A (en) * | 2013-08-08 | 2013-12-11 | 泰州市春达动物药业饲料有限公司 | Medicine composition for treating white spot syndrome virus disease and preparation method thereof |
| CN105410346A (en) * | 2015-10-30 | 2016-03-23 | 广西中医药大学 | Cultured penaeus vannamei survival rate improving traditional Chinese medicine preparation and preparation method thereof |
| KR102049976B1 (en) * | 2018-07-30 | 2019-11-28 | (주)애드바이오텍 | Antibody for shrimp’s early mortality syndrome and white spot syndrome virus, and applications thereof |
Non-Patent Citations (5)
| Title |
|---|
| SHAN L P 等: "Antiviral activity of esculin against white spot syndrome virus: A new starting point for prevention and control of white spot disease outbreaks in shrimp seedling culture", 《JOURNAL OF FISH DISEASES 》 * |
| ZHANG L 等，: "Paeonol: pharmacological effects and mechanisms of action", 《INTERNATIONAL IMMUNOPHARMACOLOGY》 * |
| 张忙友: "对虾白斑综合症的发病规律及防治方法", 《水产养殖》 * |
| 王庚申等: "白斑综合症病毒在日本囊对虾精养池塘中的动态变化", 《水产科学》 * |
| 黄永春等: "中草药和生物防控在对虾白斑综合症中的应用", 《福建农业科技》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117180246A (en) * | 2023-11-02 | 2023-12-08 | 西北农林科技大学深圳研究院 | Application of isoliquiritigenin in preparation of medicines for preventing and treating shrimp white spot syndrome |
| CN117180246B (en) * | 2023-11-02 | 2024-01-26 | 西北农林科技大学深圳研究院 | Application of isoliquiritigenin in preparation of medicines for preventing and treating shrimp white spot syndrome |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114146071B (en) | 2023-02-28 |
| CN115040497A (en) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Inhibition of a novel coumarin on an aquatic rhabdovirus by targeting the early stage of viral infection demonstrates potential application in aquaculture | |
| CN102151256B (en) | Application of protocatechuic acid in preparation of drugs for preventing and controlling livestock and poultry virus infectious diseases | |
| Yang et al. | Evaluation on the antiviral activity of ribavirin against Micropterus salmoides rhabdovirus (MSRV) in vitro and in vivo | |
| Hu et al. | Synthesis and antiviral activity of a new arctigenin derivative against IHNV in vitro and in vivo | |
| Chen et al. | Magnolol protects Ctenopharyngodon idella kidney cells from apoptosis induced by grass carp reovirus | |
| Hu et al. | Evaluation on the antiviral effect of natural product arctigenin against Micropterus salmoides rhabdovirus (MSRV) in vitro and in vivo | |
| CN114146071B (en) | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | |
| Li et al. | Antiviral activities of Glycyrrhiza uralensis components against Singapore grouper iridovirus | |
| Song et al. | Immune responses and protective efficacy on 4-(2-methoxyphenyl)-3, 4-dihydro-2H-chromeno [4, 3-d] pyrimidine-2, 5 (1H)-dione against spring viremia of carp virus in vivo | |
| Gong et al. | Dietary quercetin protects Cherax quadricarinatus against white spot syndrome virus infection | |
| CN106880630B (en) | Retro-2cyclAnd use of related derivatives | |
| NO333012B1 (en) | Use of clove oil for fish lice. | |
| CN113855654A (en) | A composition for preventing and treating coronavirus infection | |
| RU2738719C1 (en) | Agent for treating coronavirus, retrovirus infections and hepatitis c | |
| CN115998723A (en) | Application of shikimic acid in preparation of medicine for preventing and/or treating white spot syndrome of aquatic animals | |
| Qin et al. | In vitro and in vivo inhibition of a novel arctigenin derivative on aquatic rhabdovirus | |
| CN113181152B (en) | Application of Tiratricol compound in preparation of anti-EV 71 virus drugs | |
| CN102670694A (en) | Traditional Chinese medicine combination for treating porcine pseudorabies and preparation method and application thereof | |
| CN117180262B (en) | Application of galangin in preparation of shrimp white spot syndrome treatment drug | |
| CN110772510B (en) | Application of ligustilide | |
| CN102772398A (en) | Application of dihydromyricetin in preparation of drug preventing and treating influenza | |
| Zhang et al. | Cinnamaldehyde, a major component of Cinnamomum cassia Presl ethanol extract, has the potential to unlock the outbreak of WSSV | |
| CN113274379B (en) | Application of Bephenium Hydroxynaphthoate in preparation of EV 71-resistant medicines | |
| CN117180246B (en) | Application of isoliquiritigenin in preparation of medicines for preventing and treating shrimp white spot syndrome | |
| KR20160071245A (en) | A Coxsackie virus proliferation inhibitory composition extracted from Isodon excisus, and its extracting method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240407 Address after: 159 Buzheng East Road, Wangchun Industrial Park, Haishu District, Ningbo City, Zhejiang Province, 315000 Patentee after: Ningbo Sansheng Biotechnology Co.,Ltd. Country or region after: China Address before: 518000 Virtual University Park B406, R4 building, No. 19, Gaoxin South 4th Road, Yuehai street, Nanshan District, Shenzhen, Guangdong Patentee before: Shenzhen Research Institute of Northwest University of agriculture and forestry science and technology Country or region before: China |